journal
https://read.qxmd.com/read/38899395/comparison-of-the-use-of-a-clinically-implemented-deep-learning-segmentation-model-with-the-simulated-study-setting-for-breast-cancer-patients-receiving-radiotherapy
#1
COMPARATIVE STUDY
Nienke Bakx, Maurice Van der Sangen, Jacqueline Theuws, Johanna Bluemink, Coen Hurkmans
BACKGROUND: Deep learning (DL) models for auto-segmentation in radiotherapy have been extensively studied in retrospective and pilot settings. However, these studies might not reflect the clinical setting. This study compares the use of a clinically implemented in-house trained DL segmentation model for breast cancer to a previously performed pilot study to assess possible differences in performance or acceptability. MATERIAL AND METHODS: Sixty patients with whole breast radiotherapy, with or without an indication for locoregional radiotherapy were included...
June 20, 2024: Acta Oncologica
https://read.qxmd.com/read/38899394/commentary-to-incidence-of-vestibular-schwannoma-in-finland-1990-2017-pediatric-vestibular-schwannomas-an-overlooked-epidemiological-aspect
#2
JOURNAL ARTICLE
Gabriele Gaggero
No abstract text is available yet for this article.
June 20, 2024: Acta Oncologica
https://read.qxmd.com/read/38899393/a-study-of-micrornas-as-new-prognostic-biomarkers-in-anal-cancer-patients
#3
JOURNAL ARTICLE
Olav Dahl, Mette Pernille Myklebust
BACKGROUND: MicroRNA (MiR) influences the growth of cancer by regulation of mRNA for 50-60% of all genes. We present as per our knowledge the first global analysis of microRNA expression in anal cancer patients and their prognostic impact. METHODS: Twenty-nine patients with T1-4 N0-3 M0 anal cancer treated with curative intent from September 2003 to April 2011 were included in the study. RNA was extracted from fresh frozen tissue and sequenced using NGS. Differentially expressed microRNAs were identified using the R-package DEseq2 and the endpoints were time to progression (TTP) and cancer specific survival (CSS)...
June 20, 2024: Acta Oncologica
https://read.qxmd.com/read/38899392/robust-optimization-of-the-gross-tumor-volume-compared-to-conventional-planning-target-volume-based-planning-in-photon-stereotactic-body-radiation-therapy-of-lung-tumors
#4
COMPARATIVE STUDY
Thomas L Fink, Charlotte Kristiansen, Torben S Hansen, Torben F Hansen, Rune S Thing
BACKGROUND: Robust optimization has been suggested as an approach to reduce the irradiated volume in lung Stereotactic Body Radiation Therapy (SBRT). We performed a retrospective planning study to investigate the potential benefits over Planning Target Volume (PTV)-based planning. MATERIAL AND METHODS: Thirty-nine patients had additional plans using robust optimization with 5-mm isocenter shifts of the Gross Tumor Volume (GTV) created in addition to the PTV-based plan used for treatment...
June 20, 2024: Acta Oncologica
https://read.qxmd.com/read/38881342/clinical-trials-in-older-patients-with-cancer-typical-challenges-possible-solutions-and-a-paradigm-of-study-design-in-breast-cancer
#5
REVIEW
Peeter Karihtala, Aglaia Schiza, Elena Fountzilas, Jürgen Geisler, Icro Meattini, Emanuela Risi, Laura Biganzoli, Antonios Valchis
BACKGROUND AND PURPOSE: While the prevalence of older breast cancer patients is rapidly increasing, these patients are greatly underrepresented in clinical trials. We discuss barriers to recruitment of older patients to clinical trials and propose solutions on how to mitigate these challenges and design optimal clinical trials through the paradigm of IMPORTANT trial. PATIENTS AND METHODS: This is a narrative review of the current literature evaluating barriers to including older breast cancer patients in clinical trials and how mitigating strategies can be implemented in a pragmatic clinical trial...
June 17, 2024: Acta Oncologica
https://read.qxmd.com/read/38881341/application-of-comprehensive-molecular-genetic-profiling-in-precision-cancer-medicine-hungarian-experiences
#6
JOURNAL ARTICLE
Erika Tóth, Zsófia Kürönya, Edina Soós, Tamás Pintér, Henriett Butz, Zsolt Horváth, Erzsébet Csernák, Vince Kornél Grolmusz, Judit Székely, Tamás Straussz, József Lövey, Levenete Jánvári, László Báthory-Fülöp, Péter Nagy, Csaba Polgár, Attila Patócs
UNLABELLED: Recent developments in molecular genetic testing methods (e.g. next-generation sequencing [NGS]-panels) largely accelerated the process of finding the most appropriate targeted therapeutic intervention for cancer patients based on molecularly targetable genetic alterations. In Hungary, a centralized approval system following the recommendation of the National Molecular Tumor Board was launched for the coordination of all aspects of comprehensive genetic profiling (CGP) including patient selection and therapy reimbursement...
June 16, 2024: Acta Oncologica
https://read.qxmd.com/read/38881340/health-related-quality-of-life-in-danish-cancer-survivors-referred-to-a-late-effects-clinic-a-prospective-cohort-study
#7
JOURNAL ARTICLE
Lærke Kjær Tolstrup, Karin B Dieperink, Marieke Van Leeuwen, Sören Möller, Linnea Fechner, Line Helene Clausen, Thea Otto Mattsson
PURPOSE: The Region of Southern Denmark has recently established four late effects clinics to help cancer survivors suffering from complex and severe late effects. This study aimed to capture and analyze the full range of physical, mental, and psychosocial issues using patient-reported outcomes. Moreover, we aimed to describe demographic data and the type and severity of the late effects. METHODS: A prospective cohort study was conducted among cancer survivors referred to a late effects clinic...
June 16, 2024: Acta Oncologica
https://read.qxmd.com/read/38850051/relative-risk-of-second-malignant-neoplasms-highest-among-young-adult-cancer-patients-a-population-based-registry-study-in-finland
#8
JOURNAL ARTICLE
Hanna A M Koivisto, Aapeli O Nevala, Joonas M Miettinen, Janne M Pitkäniemi, Nea K Malila, Sanna M M Heikkinen
BACKGROUND AND PURPOSE: The objective of this study was to explore the incidence of second malignant neoplasms (SMNs) among adult cancer patients in Finland diagnosed with their first primary cancer (FPC) in 1992-2021. MATERIAL AND METHODS: The study used data from the population-based Finnish Cancer Registry (FCR). Risk estimates were calculated using the standardised incidence ratio (SIR), the ratio of observed second cancers compared to the expected numbers assuming the same cancer incidence as the corresponding sex-age-calendar year -split of the general population...
June 8, 2024: Acta Oncologica
https://read.qxmd.com/read/38807312/the-french-multicentric-molecular-analysis-platforms-and-personalized-medicine-trials-most-most-plus-and-megamost
#9
REVIEW
Loic Verlingue, Marine Desevre, Marie Polito, Gwenaelle Garin, Christine Rodriguez, Wang Qing, Olivier Tredan, David Perol, Isabelle Ray-Coquard, Sylvie Chabaud, Jean Yves Blay
BACKGROUND AND PURPOSE: In this manuscript we describe the academic French multicentric molecular analysis platforms including PROFILER, promoted by Centre Léon Berard, and the multicentric personalized medicine trials MOST, MOST Plus and MEGAMOST. PATIENTS/MATERIAL AND METHODS: MOST, MOST Plus and MEGAMOST comprise 14 cohorts with different targeted agents and immunotherapies. RESULTS AND INTERPRETATION: PROFILER has recruited 5,991 patients in 10 years, MOST and MOST Plus 875 patients since 2014 and MEGAMOST 172 patients since 2020, and are still ongoing...
May 28, 2024: Acta Oncologica
https://read.qxmd.com/read/38804839/immune-cell-populations-in-the-tumour-environment-following-calcium-electropora-tion-for-cutaneous-metastasis-a-histopathological-study
#10
JOURNAL ARTICLE
Mille Vissing, Sandra Sinius Pouplier, Lars Munch Larsen, Stine Krog Frandsen, Alexey Lodin, Anne-Vibeke Lænkholm, Julie Gehl
BACKGROUND AND PURPOSE: Calcium electroporation (CaEP) involves injecting calcium into tumour tissues and using electrical pulses to create membrane pores that induce cell death. This study assesses resultant immune responses and histopathological changes in patients with cutaneous metastases. PATIENTS/MATERIALS AND METHODS: The aimed cohort comprised 24 patients with metastases exceeding 5 mm. Tumours were treated once with CaEP (day 0) or twice (day 28). Biopsies were performed on days 0 and 2, with additional samples on days 7, 28, 30, 35, 60, and 90 if multiple tumours were treated...
May 28, 2024: Acta Oncologica
https://read.qxmd.com/read/38779937/a-national-precision-cancer-medicine-implementation-initiative-for-finland
#11
EDITORIAL
Katriina J Jalkanen, Erika Alanne, Sanna Iivanainen, Okko-Sakari Kääriäinen, Minna Tanner, Annika Auranen, Jussi Koivunen, Timo K Nykopp, Pia Vihinen, Mika Mustonen
No abstract text is available yet for this article.
May 23, 2024: Acta Oncologica
https://read.qxmd.com/read/38779936/desmoplastic-non-infantile-ganglioglioma-mimicking-diffuse-leptomeningeal-glioneuronal-tumor-precision-diagnostics-and-therapeutic-implications
#12
LETTER
Pitt Niehusmann, Henning Leske, Vigdis Nygaard, Hege G Russnes, Sen Zhao, Anna Latysheva, Ulrikke Straume Wiig, Birute Stankuniene, Aina Ulvmoen
No abstract text is available yet for this article.
May 23, 2024: Acta Oncologica
https://read.qxmd.com/read/38779911/impress-norway-improving-public-cancer-care-by-implementing-precision-medicine-in-norway-inclusion-rates-and-preliminary-results
#13
JOURNAL ARTICLE
Katarina Puco, Gro Live Fagereng, Sigmund Brabrand, Pitt Niehusmann, Egil Støre Blix, Eli Sihn Samdal Steinskog, Åse Haug, Cecilie Fredvik Torkildsen, Irja Alida Oppedal, Sebastian Meltzer, Åsmund Flobak, Kajsa Anna Margareta Johansson, Line Bjørge, Geir Olav Hjortland, Astrid Dalhaug, Jo-Åsmund Lund, Bjørnar Gilje, Marte Grønlie Cameron, Randi Hovland, Ragnhild S Falk, Sigbjørn Smeland, Hege Elisabeth Giercksky Russnes, Kjetil Taskén, Åslaug Helland
BACKGROUND AND PURPOSE: In Norway, comprehensive molecular tumour profiling is implemented as part of the public healthcare system. A substantial number of tumours harbour potentially targetable molecular alterations. Therapy outcomes may improve if targeted treatments are matched with actionable genomic alterations. In the IMPRESS-Norway trial (NCT04817956), patients are treated with drugs outside the labelled indication based on their tumours molecular profile. PATIENTS AND METHODS: IMPRESS-Norway is a national, prospective, non-randomised, precision cancer medicine trial, offering treatment to patients with advanced-stage disease, progressing on standard treatment...
May 23, 2024: Acta Oncologica
https://read.qxmd.com/read/38779910/pcm4eu-and-prime-rose-collaboration-for-implementation-of-precision-cancer-medicine-in-europe
#14
JOURNAL ARTICLE
Kjetil Taskén, Soemeya F Haj Mohammad, Gro Live Fagereng, Ragnhild Sørum Falk, Åslaug Helland, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Katarina Steen Carlsson, Bettina Ryll, Katriina Jalkanen, Anders Edsjö, Hege G Russnes, Ulrik Lassen, Ebba Hallersjö Hult, Iwona Lugowska, Jean-Yves Blay, Loic Verlingue, Edvard Abel, Maeve A Lowery, Matthew G Krebs, Kristoffer Staal Rohrberg, Kristiina Ojamaa, Julio Oliveira, Henk M W Verheul, Emile E Voest, Hans Gelderblom
BACKGROUND: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful. PATIENTS AND METHODS: PCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries...
May 23, 2024: Acta Oncologica
https://read.qxmd.com/read/38779869/agent-orange-exposure-and-prostate-cancer-risk-in-the-million-veteran-program
#15
JOURNAL ARTICLE
Meghana S Pagadala, Asona J Lui, Allison Y Zhong, Julie A Lynch, Roshan Karunamuni, Kyung Min Lee, Anna Plym, Brent S Rose, Hannah K Carter, Adam S Kibel, Scott L DuVall, J Michael Gaziano, Matthew S Panizzon, Richard L Hauger, Tyler M Seibert
BACKGROUND: The US government considers veterans to have been exposed to Agent Orange if they served in Vietnam while the carcinogen was in use, and these veterans are often deemed at high risk of prostate cancer (PCa). Here, we assess whether presumed Agent Orange exposure is independently associated with increased risk of any metastatic or fatal PCa in a diverse Veteran cohort still alive in the modern era (at least 2011), when accounting for race/ethnicity, family history, and genetic risk...
May 23, 2024: Acta Oncologica
https://read.qxmd.com/read/38779868/the-evolution-of-precision-oncology-the-ongoing-impact-of-the-drug-rediscovery-protocol-drup
#16
JOURNAL ARTICLE
Soemeya F Haj Mohammad, Hans J L Timmer, Laurien J Zeverijn, Birgit S Geurts, Ilse A C Spiekman, Karlijn Verkerk, Florentine A J Verbeek, Henk M W Verheul, Emile E Voest, Hans Gelderblom
BACKGROUND AND PURPOSE: The Drug Rediscovery Protocol (DRUP) is a Dutch, pan-cancer, nonrandomized clinical trial that aims to investigate the efficacy and safety of targeted and immunotherapies outside their registered indication in patients with advanced or metastatic cancer. PATIENTS: Patients with advanced or metastatic cancer are eligible when there are no standard of care treatment options left and the tumor possesses a molecular genomic variant for which commercially available anticancer treatment is accessible off-label in DRUP...
May 23, 2024: Acta Oncologica
https://read.qxmd.com/read/38779867/the-tumor-immune-microenvironment-in-breast-cancer-progression
#17
REVIEW
Marit Otterlei Fjørtoft, Kanutte Huse, Inga Hansine Rye
BACKGROUND: The tumor microenvironment significantly influences breast cancer development, progression, and metastasis. Various immune cell populations, including T cells, B cells, NK cells, and myeloid cells exhibit diverse functions in different breast cancer subtypes, contributing to both anti-tumor and pro-tumor activities. PURPOSE: This review provides an overview of the predominant immune cell populations in breast cancer subtypes, elucidating their suppressive and prognostic effects...
May 23, 2024: Acta Oncologica
https://read.qxmd.com/read/38770722/treatment-of-vulvar-cancer-recurrence-with-electrochemotherapy-a-case-control-study
#18
JOURNAL ARTICLE
Gregor Vivod, Masa Omerzel, Nina Kovacevic, Gorana Gasljevic, Ines Cilensek, Gregor Sersa, Maja Cemazar, Sebastjan Merlo
BACKGROUND: Electrochemotherapy (ECT) is a combined treatment method based on electroporation and simultaneous chemotherapy. In cases where radiotherapy has previously been used, surgery is often the only treatment option for vulvar cancer recurrence with potential resection of clitoris, vagina, urethra or anal sphincter. The unique advantage of ECT is its selectivity for cancer cells while sparing the surrounding healthy tissue. The aim of the study was to compare the ECT treatment of vulvar cancer recurrence for non-palliative purposes with surgical treatment...
May 21, 2024: Acta Oncologica
https://read.qxmd.com/read/38751329/evaluation-of-sex-inequity-in-lung-cancer-specific-survival
#19
JOURNAL ARTICLE
Dan Lærum, Trond-Eirik Strand, Odd Terje Brustugun, Frode Gallefoss, Ragnhild Falk, Michael T Durheim, Lars Fjellbirkeland
BACKGROUND: Whether sex is an independent prognostic factor in lung cancer survival is the subject of ongoing debate. Both large national registries and single hospital studies have shown conflicting findings. In this study, we explore the impact of sex on lung-cancer-specific survival in an unselected population that is well-characterized with respect to stage and other covariates. MATERIAL AND METHODS: All patients diagnosed with lung cancer at a single hospital serving a whole and defined region in Southern Norway during the 10 years 2007-2016 were included...
May 15, 2024: Acta Oncologica
https://read.qxmd.com/read/38745484/progress-against-lung-cancer-denmark-2008-2022
#20
JOURNAL ARTICLE
Marianne Steding-Jessen, Henriette Engberg, Erik Jakobsen, Torben Riis Rasmussen, Henrik Møller
BACKGROUND AND PURPOSE: There has been marked progress against lung cancer in Denmark. To gain further insight into the different aspects of the improvement, we examined the stage-specific incidence rates, stage-specific survival and mortality rates. MATERIALS AND METHODS: We used information from the Danish Lung Cancer Registry on date of diagnosis and clinical stage to calculate age-standardised incidence rates and patient survival by sex, period and stage. Information about age-standardised lung cancer-specific mortality rates by sex and period was extracted from The Danish Health Data Authority...
May 14, 2024: Acta Oncologica
journal
journal
29603
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.